Connect with us

Business

Alberta reports 500 COVID-19 cases on Sunday after low test numbers on Christmas Day – CTV Edmonton

Published

 on


EDMONTON —
Alberta reported 500 cases of COVID-19 on Sunday, but only 6,900 tests were processed the day before.

Dr. Deena Hinshaw noted that the numbers were lower because fewer people were tested on Christmas Day.

The positivity rate currently sits at 7 per cent for the province, and hospitalizations and ICU admissions are stable.

The number of deaths has not been released.

Comprehensive updates are scheduled to resume in the new year.  

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Trudeau speaks to Pfizer CEO as delays to vaccine shipments get worse – CP24 Toronto's Breaking News

Published

 on


MIa Rabson, The Canadian Press


Published Thursday, January 21, 2021 4:39PM EST


Last Updated Thursday, January 21, 2021 8:00PM EST

OTTAWA – Prime Minister Justin Trudeau spoke to Pfizer CEO Albert Bourla by phone Thursday, the same day the company informed Canada delays to its shipments of COVID-19 vaccines are going to be even worse than previously thought.

Maj.-Gen. Dany Fortin, the military commander now overseeing the vaccine logistics for the Public Health Agency of Canada, said last week a factory expansion at Pfizer’s Belgium plant was going to slow production, cutting Canada’s deliveries over four weeks in half.

In exchange, Pfizer expects to be able to ship hundreds of millions more doses worldwide over the rest of 2021.

Tuesday, Fortin said Canada would receive 80 per cent of the previously expected doses this week, nothing at all next week, and about half the promised deliveries in the first two weeks of February.

Thursday, he said the doses delivered in the first week of February will only be 79,000, one one-fifth of what was once expected. Fortin doesn’t know yet what will come the week after, but overall, Canada’s doses over three weeks are going to be just one-third of what had been planned.

Trudeau has been under pressure to call Bourla, as the delayed doses force provinces to cancel vaccination appointments and reconsider timing for second doses.

Fortin said some provinces may be hit even harder than others because of limits on the way the Pfizer doses can be split up for shipping. The vaccine is delicate and must be kept ultra frozen until shortly before injecting it. The company packs and ships specialized coolers, with GPS thermal trackers, directly to provincial vaccine sites.

Ontario Premier Doug Ford said earlier this week he doesn’t blame the federal government for the dose delays but wanted Trudeau to do more to push back about it.

“If I was in (Trudeau’s) shoes … I’d be on that phone call every single day. I’d be up that guy’s yin-yang so far with a firecracker he wouldn’t know what hit him,” he said of Pfizer’s executives.

Trudeau informed Ford and other premiers of the call with Bourla during a regular teleconference to discuss the COVID-19 pandemic. Until Thursday, all calls between the federal cabinet and Pfizer had been handled by Procurement Minister Anita Anand.

Ford also spoke to Pfizer Canada CEO Cole Pinnow Wednesday.

Trudeau didn’t suggest the call with Bourla made any difference to the delays, and noted Canada is not the only country affected.

Europe, which on the weekend thought its delayed doses would only be for one week after European Commission President Ursula von der Leyen spoke to Bourla, now seems poised to be affected longer. Italy is so angry it is threatening to sue the U.S.-based drugmaker for the delays.

Mexico said this week it is only getting half its expected shipment this week and nothing at all for the next three weeks. Saudi Arabia and Bahrain also reported delays getting doses. Pfizer Canada spokeswoman Christina Antoniou said more countries were affected but wouldn’t say which ones.

Fortin said Pfizer has promised to deliver four million doses to Canada by the end of March and that is not going to change with the delay. With the current known delivery schedule, the company will have to ship more than 3.1 million doses over 7 1/2 weeks to meet that commitment.

Deliveries from Moderna, the other company that has a COVID-19 vaccine approved for use in Canada, are not affected. Canada has received about 176,000 doses from Moderna to date, with deliveries arriving every three weeks.

Moderna has promised two million doses by the end of March.

Both vaccines require first doses and then boosters several weeks later for full effectiveness. Together Pfizer and Moderna intend to ship 20 million doses to Canada in the spring, and 46 million between July and September. With no other vaccines approved, that means Canada will get enough doses to vaccinate the entire population with two doses by the end of September.

This report by The Canadian Press was first published Jan. 21, 2021.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

New Public Health Order Finalized, Changes Made To Gathering Size – Steinbachonline.com – SteinbachOnline.com

Published

 on


[unable to retrieve full-text content]

  1. New Public Health Order Finalized, Changes Made To Gathering Size – Steinbachonline.com  SteinbachOnline.com
  2. Eased code red restrictions for parts of Manitoba take effect Saturday  CTV News
  3. Manitoba to allow 2 visitors in homes starting Saturday for all but northern region  CBC.ca
  4. Northern Manitoba COVID-19 surge continues, as region reports more than half of province’s 198 new cases  CBC.ca
  5. Northern Manitoba continues to be hit hard by COVID-19; five new deaths in Manitoba  CTV News Winnipeg
  6. View Full coverage on Google News



Source link

Continue Reading

Business

Don't downplay mRNA: Experts say new technology could change the vaccine landscape – CTV News

Published

 on


When drug companies like Pfizer and Moderna learned to successfully incorporate messenger RNA technology into a COVID-19 vaccine, experts say they likely opened the door to a significant shift in the future of immunization.

The milestone in vaccine development was met with enthusiasm from most, but the seemingly swift pace and novel approach is causing hesitancy in others.

Experts say the new technique shouldn’t dissuade people from getting the vaccine. While the mRNA method is new to inoculations, the actual technology has been around for decades.

The difference now, they say, is scientists have ironed out the kinks to make a useful product.

“It sounds fancy, mRNA, but there’s nothing outlandish about it,” said Dr. Earl Brown, a virology and microbiology specialist with the University of Ottawa. “This is the way our cells operate — we live by mRNA.”

Vaccines from Pfizer-BioNTech and Moderna were the first inoculations approved for humans to use mRNA, which provides our cells with instructions to make proteins. In the case of COVID vaccines, the injected material shows cells how to make a harmless piece of the coronavirus spike protein, which then teaches our immune system to recognize the virus and fight off a future infection.

Scientists made the vaccine by programming genetic material from the spike protein into mRNA, a process that theoretically could work for other viruses.

“As long as you know how to create those instructions — that genetic code you need to convince your body to create that target — you can design an mRNA vaccine against any antigen,” said Nicole Basta, an associate professor of epidemiology at McGill.

“But the question is whether it will be effective, and whether it will be safe.”

The development of future mRNA vaccines might be quick, Basta says, but they would need to go through the usual evaluation process and clinical trials to ensure safety and efficacy. So vaccines for other viruses won’t be popping up overnight.

Still, Basta adds, there’s potential for using mRNA to either improve upon existing vaccines or to develop new ones against other pathogens.

Dr. Scott Halperin, a professor at Dalhousie University and the director of the Canadian Centre for Vaccinology, sees mRNA vaccines as “evolutionary rather than revolutionary.”

Part of the reason COVID vaccines came together so quickly was the technology had been developing for years, Halperin said. The global pandemic offered scientists a pressing opportunity — and unprecedented funding and collaboration — to try again for a viable injection.

Previous research had been done on creating mRNA vaccines against Zika and other viruses, Halperin added, and there were earlier efforts focused on cancer treatments. Coronavirus-specific research was further sped up by spike protein analysis from SARS and MERS.

While the mRNA technology itself is impressive, Halperin says improvements need to be made to create a more temperature-stable product before these types of vaccines and treatments “truly take over.”

“The logistics of delivering mRNA vaccines right now, we wouldn’t want to have to do that for every vaccine we produce,” he said, referencing the ultra-cold storage temperature that’s currently needed. “But I do think it’s an important milestone.”

Scientists are expected to continue advancing the technology, just as they did recently in solving two confounding problems with mRNA — its fragility and instability.

Brown says fragility was resolved by packaging the mRNA in a fat coating, giving it something to help bind onto cells so it wouldn’t disintegrate upon injection. The instability was conquered by modifying the uracil component of RNA, one of the four units of its genetic code.

“The technology application is new, but the science is mature,” Brown said. “We’ve just reached the point at which we can apply it.”

Traditional vaccines typically contain a killed or weakened virus, Brown said. Those methods are still being used in COVID vaccine development, including by AstraZeneca-Oxford, whose product has not yet been approved in Canada.

A benefit to using mRNA is the speed at which a vaccine can be developed or updated once scientists know what to target, Brown says.

While experts believe current vaccines will work against recent variants of the COVID virus — including one originating in the U.K. that’s more transmissible — Brown says mRNA’s adaptability could theoretically come in handy if new strains emerged that necessitated an update.

“In six weeks they could produce something,” he said. “It would still have to go through Phase 3 trials, but it does give you more flexibility and a big leg up.”

This report by The Canadian Press was first published Jan. 21, 2021.

Let’s block ads! (Why?)



Source link

Continue Reading

Trending